T HE WELL-KNOWN hypotensive effect of several saluretic compounds of the benzothiadiazine series has commonly been ascribed to their saluretic properties, hypotension resulting either from hypovolemia consequent to extracellular sodium loss1, 2 or from various changes in body water and eleetrolyte balance. 3 6 Interest has recently been raised by the report7' 8 that 3-methyl-7-chloro-1,2,4-benzothiadiazine-1,1-dioxide (SRG 95213, diazoxide), a compound differing from the known benzothiadiazine drugs by the elimination of the sulfamyl group from the benzenoid moiety, has no natriuretic or diuretic activity, although retaining definite hypotensive properties. The following is a report of our clinical experience with this drug during the last months: particular attention has been paid not only to the blood pressure effects of diazoxide, but also to its action on kidney function and on water and electrolyte balance.
Materials and Methods
The drug has been tested either by single or by repeated administration in 20 patients with primary arterial hypertension of mild to moderate degree. Several subjects had some secondary vascular, myocardial, or kidney involvement, but none had history or signs of congestive heart failure. All subjects except three were hospitalized.
Arterial blood pressure was measured with the auscultatory method each nmorning (or each second morning in the three outpatients) by the same observer, with the patient in the lying and then in the standing position. Sodium and potassium were measured in blood and urine by flame photometry; urine chloride was determined by the method of Volhard and Harvey, as modified by Peters and van Slyke,9 urine bicarbonates were measured in a manometric van Slyke apparatus, and titrable acidity was measured according to Henderson 
Results

Effects of Diazoxide on Arterial Pressure Single Dose Administration
Diazoxide was administered to eight hypertensive patients in single oral doses of 100 to 300 mg. Control blood pressure was taken in the lying position after the patient had become accustomed to the experimental con ditions, and when at least four consecutive readings had given coneordant results. In all subjects but one, arterial pressure started to decrease after 30 minutes and reached the lowest level within 60 to 90 minutes after oral administration, the maxinial effect being maintained for at least 4 hours. The decrease in mean arterial pressure ranged from 10 to 55 mm. Hg ( fig. 5 ). It should be noted that the only patient who did not show a hypotensive response was the only one receiving a 100-mg. dose of the drug.
Prolonged Administration
Prolonged administration of diazoxide was tested in 17 hypertensive subjects, 14 of them being hospitalized and three outpatients. The experimental period was delayed for 5 to 7 days after admnission until the blood pressure remained at the same level for 3 consecutive days. During the experimental period, which ranged from 20 to 102 days in the different patients, placebo and diazoxide were administered accordingf to a crossed design, and in a few subjects hydrochlorothiazide, alone or in association with diazoxide, was also tested. Circulation Diazoxide was administered by the oral route in single daily doses of 200 to 400 mg. for periods extending up to 49 days. For the whole period of treatnient with diazoxide there was a decrease of recumbent systolic blood pressure averaging 32, of recumbent diastolic pressure averaging 17, of standing systolic pressure averaging 27, and of standing diastolic pressure averaging 15 mm. Hg. An analysis of variance with nmultiple classification of average pressure values during prolonged placebo or diazoxide administration (table 1) shows that both systolic and diastolic blood pressures were consistentlv and durably decreased by the drug both in the lying and the standing positions (p < .01).
A further analysis of variance indicates that in our patients the drug was equally effective either in the lying or in the standing position (table 2).
All patients tested responded favorably, at least to a 400-mg. dose of diazoxide, except one subject. It should be noted, however, that only cases of mild to moderate severity were studied. Blood pressure decrease was always rapidly achieved upon taking the drug, and promptly disappeared when diazoxide was substituted by a placebo ( fig. 1 ). No instance of tolerance to the drug was noticed, at least for the relativelv short periods of our observations (up to 49 days) ; however, phases of transient escape from blood pressure control, lasting 1 or 2 days, occurred not infrequently during prolonged treatment. Although a statistical analysis was not attempted, due to the linited nuimber of our observations, in the six patients tested, the addition of hydrochlorothiazide (25 to 50 mg. daily) to diazoxide had hypotensive effects larger than those induced by either drug alone ( fig. 2 ).
Effects of Diazoxide on Water and Electrolyte Excretion, Plasma Volume, and Body Weight Single Dose Administration
This study was carried out in six hypertensive patients maintained in a metabolic ward at a constant diet containing 140 mEq. of sodium, 45 mEq. of potassium, 135 mEq. of chloride, and 1,500 ml. of water. Sodium, potassium, chloride, bicarbonate, hydrogen ion, and water excretion was measured in three 2-hour samples, takein at 11 a.m., 1 p.m., anid 3 p.m. and in three 6-hour samples, taken at 9 p.m., 12 p.m., and 6 a.m. Both placebo and drug were given in a single dose at The excretion values for at least 4 days after initiation of the diet were discarded, and only those of the 2 days inimediately preceding diazoxide administration were used as controls. In each patient, 200 and 400 mg. of diazoxide were successively tested, a week interval being allowed between the two trials (table 3) . Excretion of water, as well as of sodium, chloride, and bicarbonate ions was decreased by administration of diazoxide, a fact confirmed by analyses of variance with multiple classification (tables 4 and 5). There was no clear change in potassium and hydrogen ion excretion, but the limited size of our sample does not allow any definite conclusion on this point.
The effects on the water and electrolyte balance of diazoxide and hydrochlorothiazide are compared in figure 3 , which refers to one of the patients of the study. While hydrochlorothiazide is a powerful natriuretic, as well as chloruretic agent, diazoxide is a sodium and chloride-retaining drug (chloride is not shown Meanis (x) anid stantdardL deviations (s) of six hypertensive patients. Values indicated un(ler "'placebo" are uleanis of values measured during the 2 dlays preceding administration of diazoxide. -.
It should be pointed out that no constant = 3000correlation was found between changes in . plasma volume and body weight in the pa-> 2000 tients receiving diazoxide (fig. 4) . The correlation coefficient is only r -0.363, and its significance insufficient (0. (table 7) . Althougyh meanl arterial press-ure was markedly decreased in all cases, in no inistance was glomerular filtration rate also decreased; to the contrary, it was definitely increased in at least four patients.
Likewise, renial plasmia flow increased strik-ingly in two subjects and slightly in two, and was decreased, although iuoderately, in the remainiing two. Discussion While we do not know of any extensive report on the clinical action of diazoxide, our observations seem well consistent with a few reports that have recently appeared in abstract form.3' 14 These observations on the hemodynamic and renal effects of the drug are worthy of comment. In mild and moderate hypertensive patients diazoxide appears to be an effective antihypertensive agent, affecting diastolic as well as systolic blood pressure with no appreciable difference either in the lying or the standina position. This finding suggests that hypotension is mainlv obtained through arteriolar vasodilatation rather than through reduction of cardiac output. Expansion of plasma volume hints that cardiac output may even be increased during diazoxide treatment.
The sodium-retaining action of diazoxide is of some interest. It is quite marked and associated with water retention, and tends to have cumulative effects during prolonged treatment. While other antihypertensive drugs, for example guanethidine, are known to retain sodium and water,15 the action of diazoxide is peculiar: indeed, the sodium-retaining effect of guanethidine results from a simultaneous decrease in glomerular filtration rate, but sodium retention is induced by diazoxide in spite of an increase, or at least no change, in glomerular filtration. This suggests that diazoxide affects tubular handling of electrolytes, at the same site, though in the opposite way as the classical benzothiadiazine drugs with saluretic activity. Furthermore, our observation that during prolonged treatment with Circulation, Volume XXVII, May 1968 diazoxide the increase in plasma, and presumably in extracellular fluid volume, does not parallel the increase in body weight, and presumably in total body water, suggests that diazoxide administration may induce a shift in water from the intracellular to the extracellular compartment. Should this hypothesis be confirmed by more direct measurements of intracellular and extracellular fluid volumes, diazoxide might be postulated to act nmore broadly on the ion exchange at the cell membrane rather than strictly on renal tubular mechanisms only.
The marked hypotensive effect of a benzothiadiazine compound deprived of saluretic action might appear to weaken considerably + 300. * 
901
I the current hypothesis that hypotension induced by chlorothiazide and its analogues is due to sodium and water loss.1, 2 Although the latter hypothesis has already been shown to hold only during early treatment,2-4' 6 the late hypotensive effects of the saluretic benzothiadiazines have been postulated to result from the continued loss of potassium from the intracellular environment and redistribution of ions across the cell membrane.6 While a direct vasodilator effect of diazoxide cannot be ruled out in the absence of crucial evidence against it, it does not seem without significance that this drug is also endowed with a primary action on electrolyte and water exchange at the renal tubular, and probably at the cell membrane, level. The hypothesis that both natriuretic and sodium-retaining benzothiadiazine compounds affect blood pressure through some ion disturbance seems worthy of further investigation. Finally, the clinical usefulness of diazoxide as an antihypertensive agent should be discussed. On the one hand, its definite effectiveness, at least in mild and moderate cases, on both systolic and diastolic pressures with no differenee either in the lying or the standing position, the frequently observed increase in glomerular filtration rate and in renal plasma flow suggest it as a very convenient drug in the treatment of moderate hypertension. On the other hand, the consequences of sodium retention may cause some concern. Although we have not observed any case of edema, it is conceivable that edema and congestive heart failure might well develop in hypertensive patients with impaired heart function. Prolonged administration of diazoxide for several months should help in clarifying whether sodium retention and increase in plasma volume are continuingr during progressive treatment or are gradually compensated in late periods.
The problem of pancreatic toxicity should be carefully investigated, though it seems to be common to treatment with all benzothiadiazine compounds.'12 16, 17 If an aggravation of this potential danger is discounted, the tssQciation of sodium-retainingf and saluretic benzothiadiazine drugs might be of some advantage in permitting a good hypotensive response without gross fluid retention or electrolyte loss. Summary Diazoxide, a new compound of the benzothiadiazine group, has been shown to decrease both systolic and diastolic arterial pressure in mild or moderate hypertensive patients, even though it lacks the saluretic properties characteristic of the other known compounds of the group.
Instead of promoting sodium excretion, diazoxide appears to be a powerful sodiumand chloride-retaining agent, its prolonged use leading to important increases in plasma volume and body weight, and probably to some redistribution between extracellular and intracellular fluid. Glomerular filtration rate and renal plasma flow are often increased during treatment with the drug.
Although diazoxide was in several respects a useful hypotensive agent, at least in hypertensive patients without heart failure, it may share with other benzothiadiazine compounds some pancreatic toxicity. a side effect that should be carefully considered during benzothiadiazine treatment.
